Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study

November 22, 2017

The Effect of Food on the Absorption of Abiraterone Acetate from a Fine Particle Dosage Form: A Randomized Crossover Trial in Healthy Volunteers

November 16, 2017

Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA™ by the U.S. FDA

KING OF PRUSSIA, Pa., July 20, 2017 /PRNewswire/ -- Churchill Pharmaceuticals, LLC (Churchill), a privately held company devoted to expanding treatment options...

July 20, 2017

Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate

Click here to view the article.

July 10, 2017

Churchill Pharmaceuticals Expands Commercial Leadership Team

King of Prussia, PA., May 30, 2017 Churchill Pharmaceuticals, LLC (Churchill), a clinical-stage biopharmaceutical company, today announced the expansion of...

May 30, 2017

Churchill Pharmaceuticals Announces Submission of NDA for Novel Oral Formulation of Prostate Cancer Treatment

King of Prussia, PA., May 23, 2017 Churchill Pharmaceuticals, LLC (Churchill) today announced it has submitted a New Drug Application...

May 23, 2017

Churchill Pharmaceuticals launches a new updated website with a fresh design

King of Prussia, PA., May 16, 2017 Churchill Pharmaceuticals, a drug development biopharmaceutical company specialized in oral oncology, announced the...

May 22, 2017

Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects, Clinical Pharmacokinetics 2017

Click here to view the article.

May 5, 2017